ISBT 2006 Abstracts

Adobe Acrobat required for viewing Abstracts. Download it free here.

To save an abstract, right click, and choose "Save Target As".

• Detection of HIV-1 Infection in Blood Donors During the Immunological Window Period by the Implementation of Nucleic Acid Amplification Technology
• NAT HBV: Transfusion Safety and Infective Residual Risk
• HBV-DNA and HBcAb IgG in Blood Donor's Population
• Hepatitis B and Molecular Screening Assays: Evidence for Different Outcomes of this Infection
• Yield of Minipool and Individual Donation Nucleic Acid Amplification Testing for West Nile Virus RNA in United States Blood Donors, 2003-2005
• The Contribution of Nucleic Acid Testing (NAT) in Blood Transfusion Safety. Detection of Four NAT HBV DNA Positive, HBS AG Negative in Single Blood Donations
• Head To Head Comparison of Two New Automated NAT Systems Chiron PROCLEIX^® TIGRIS^® System vs Roche Cobas s 201
• Window Period of HIV Infection in a Repeat Blood Donor
• Nucleic Acid Testing (NAT) Performance in HBsAg Positive Blood Donations
• Interpretation of HBV NAT Results in Healthy Subjects
• Acute Phase and Occult HBV Infections with Multiple Mutations in the Surface Antigen 'A' Determinant Detected by HBV/HCV/HIV-1 TMA Screening of Spanish Blood Donors
• Analytical Performance of PROCLEIX Duplex and Triplex TMA Assays in an Historical Proficiency Programme
• An HCV Seroconversion Detected Using a NAT Test Procedure During Screening of Blood and Blood Components in a Donor Population in Italian Campania Region
• Individual Hepatitis B Virus Nucleic Acid Testing (HBV-NAT) on 61.825 Blood Donations in Madrid, Spain
• Evaluation of Single NAT in a National Blood Services
• Simultaneous Screening for HCV, HIV-1 and HBV in Blood Donations with the Fully Automated System
• Quality Control Programme for Nucleic Acid Screening in Blood Service Laboratories
• HBV and HCV Infected Blood Donations Interdicted by Individual Donation Nucleic Acid Testing (ID-NAT) in Lithuania
• Analytical and Clinical Performance of the PROCLEIX^® ULTRIO^® HIV-1/HCV/HBV Assay in Low Viral Load Samples
• The Importance of Implementing the HBV DNA Screening Using NAT Testing for Transfusional Validation in a High Risk Area
• HCV, HIV-1, HBV Molecular Screening for Blood Donation: From Semi-Automated Systems to the Fully Automated Instrument Platform
• Comparison of the CHIRON PROCLEIX^® TIGRIS^® and ROCHE s 201 Nucleic Acid Testing (NAT) Sysytems for Simultaneous Detection of HIV/HCV RNA and HBV DNA
• Benefits of the Test Chiron PROCLEIX^® ULTRIO^® Assay HCV/HIV/HBV in the Improvement of Blood Safety
• HCV, HIV, HBV Genome Detection in Blood Donors with the Use of New Molecular Assay
• Early Experience with Individual Donation HBV/HCV/HIV-1 Nucleic Acid Amplification Testing (ID-NAT) in the South African National Blood Service
• NAT Screening for HIV/HCV (PROCLEIX, CHIRON) in a Single Donation in Coimbra, Portugal (2000-2006)
• Evaluation of Accepted Blood Donors with a Multiplex Nucleic Acid Test (NAT) at Chiang Mai University Hospital, Thailand
• NAT Screening for HCV, HIV and HBV on Blood Donations in Italy
• Analytical Performance Characteristics of the PROCLEIX^® ULTRIO^® HIV-1/HCV/HBV Assay on TIGRIS in a Large Scale Evaluation of Individual Donation NAT in South Africa